10-Aug-2022

Kazia Therapeutics’ oncology drug paxalisib continues to generate positive trial data

Kazia Therapeutics CEO James Garner joins Small Caps to discuss the company’s ongoing development of its lead drug paxalisib, which recently generated positive interim data in a phase one clinical trial for treating brain metastases.

08-Aug-2022

Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference

Interim data from the study reveals a complete or partial response in all evaluable trial participants for a disease with a poor prognosis and limited current options.

12-Jul-2022

Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer

Kazia has launched a new Scientific Advisory Board (SAB) consisting of four distinguished clinicians and scientists with expertise in the development of innovative therapies for brain cancer.

07-Jul-2022

Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer

Kazia has been awarded a Rare Paediatric Disease Designation (RPDD) by the US Food and Drug Administration (FDA) for the use of paxalisib in the treatment of atypical rhabdoid/teratoid tumours (AT/RT), a rare and highly aggressive childhood brain cancer.

06-Jul-2022

Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining

The US FDA has awarded Kazia Therapeutics (ASX:KZA) a designation for its treatment for rare brain cancer in children. 

06-Jul-2022

V-Con: Small Cap Showcase - Kazia Interview and Presentation

30-Jun-2022

Kazia Therapeutics continues to make good progress on cancer treatment assets

Kazia is making good progress with its two pipeline assets, paxalisib and EVT801, with the latter having cleared third dose level and is recruiting well.

The company also notes the GBM AGILE pivotal study has opened in France, the fourth country to start recruitment to the paxalisib arm.

14-Jun-2022

Kazia Therapeutics presents ‘positive data’ on paxalisib in childhood brain cancers

“Positive data” is being presented regarding the activity of Kazia's lead drug paxalisib in two forms of childhood brain cancers.

The company is presenting the data via two presentations this week at the 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) in Germany.

08-Jun-2022

Kazia onto next chapter in Phase 2 brain metastases trial

Dr James Garner provides an update on the oncology company's lead program, a glioblastoma treatment candidate known as paxalisib.

31-May-2022

GBM AGILE OPENS TO PAXALISIB IN EUROPE

Kazia Therapeutics has announced that the GBM AGILE study in glioblastoma has opened recruitment to the paxalisib arm in Europe.

17-May-2022

KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE

Kazia Therapeutics marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased focus on childhood brain cancer among policymakers.

02-May-2022

Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting

Kazia CEO Dr James Garner tells Andrew Scott about the company's quarterly achievements, including data the company presented at the American Association of Cancer Research (AACR) conference on the use of its asset paxalisib in a rare, aggressive childhood cancer. It has been a busy quarter for the company on the trials front, and news for investors is good too, with the company introducing an at-the-market financing facility in the US - a quick and efficient way of transacting on biotech shares.

30-Apr-2022

Kazia to present final data from paxalisib phase II study as ASCO

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology (ASCO).

28-Feb-2022

Kazia Therapeutics recruits first keto patient to Phase II paxalisib study for treatment of glioblastoma

Kazia Therapeutics (ASX: KZA)has recruited its first patient into a Phase II study of investigational new drug paxalisib for the treatment of newly-diagnosed and recurrent glioblastoma.

14-Feb-2022

Kazia Therapeutics advances human trials for lead cancer drugs during December quarter

Oncology-focused and clinical stage biotechnology company Kazia Therapeutics (ASX: KZA) has reported strong progress on the development of its lead drug candidates during the three months to 31 December.

07-Feb-2022

Kazia Therapeutics To Present At BIO CEO Conference

Kazia Therapeutics Limited will be presenting at the BIO CEO Conference, to be held in person and virtually in New York, NY, from 14-17 February 2022. Kazia will be presenting in person on day one of the conference, Monday, 14 February. The presentation will provide an update on recent progress with Kazia's two clinical-stage oncology programs and will cover some of the important catalysts expected during 2022

14-Dec-2021

Kazia Therapeutics Appoints Karen Krumeich As Chief Financial Officer

In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022.

04-Dec-2021

Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

The study tested paxalisib's effectiveness in patients whose genetic profile confers resistance to the only other treatment available for this condition. Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA), a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib – a first-line therapy in patients with glioblastoma.

02-Dec-2021

Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The results confirm the previously reported safety and efficacy profile with paxalisib in this high unmet need disease.

29-Nov-2021

GBM AGILE Opens to Paxalisib in Canada

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health Sciences Centre in Toronto, Ontario. This marks the first Canadian site to open to paxalisib, and the first opportunity for Canadian patients to access the drug.